CHINESE HEALTH TECHNOLOGY PARK OFFERS UNIQUE CONFERENCE OPPORTUNITY

February 04, 2002 - The Chinese Health Technology Park in conjunction with The State Drug Administration of China is pleased to announce the Foreign Pharmaceutical Enterprises in China conference, to present the investment, challenges & opportunities for Pharmaceutical organisations in China after joining World Trade Organisation (WTO). This is the first European opportunity to meet face to face with the top-level delegates responsible for the Chinese Pharmaceutical and Medical Policies.

February 04, 2002 - The Chinese Health Technology Park in conjunction with The State Drug Administration of China is pleased to announce the Foreign Pharmaceutical Enterprises in China conference, to present the investment, challenges & opportunities for Pharmaceutical organisations in China after joining World Trade Organisation (WTO). This is the first European opportunity to meet face to face with the top-level delegates responsible for the Chinese Pharmaceutical and Medical Policies.

Chinas accession to the WTO presents both domestic and foreign drug manufacturers with enormous opportunities, and multinational pharmaceutical companies the potential to acquire a large share of the Chinese pharmaceutical market (China's State Drug Administration estimates that multinational companies will control 70 percent of the market).

The conference, scheduled for the 28 February 2002 in Frankfurt, Germany will specifically explore:
- Opportunities and challenges for overseas investments in China after China's WTO entry
- How the rules and regulations governing the medical industry will change in the future
- Introduction of the pharmaceutical policy in China
- The policy for drugs registration and new drugs research and development
- Introduction of NHTP
- The current medical market in China and the development trend
- The current medical market development and investment opportunities in China

For any pharmaceutical company considering entry into the Chinese market, this is an ideal opportunity to raise issues or concerns, with officials openly discussing 'What will happen to The Chinese Pharmaceutical Market after WTO entry and how Foreign Pharmaceutical companies should react to the changes'.

The global pharmaceutical industry has turned its focus on China. The question everyone is asking is about the likely shape of the Chinese pharmaceutical industry since joining the WTO?